Plant-based AI GB Sciences leverages an AI-powered platform (PhAROS) and plant-derived mixtures to target multi-billion-dollar markets, presenting a sales angle to investors and biopharma partners interested in novel, plant-inspired therapeutics.

Parkinson's Focus With five late preclinical programs and a lead Parkinson’s disease therapy prepped for First-in-Man trials, there is a clear capability for partnerships or licensing deals to accelerate clinical development and global expansion in neurodegenerative research.

Global IP Portfolio A substantial patent estate with issued patents protecting 28 formulas and pending patents covering 25 formulas signals strong defensibility and potential for licensing, co-development, or exclusive regional rights with pharma and biotech companies.

Strategic Partnerships Collaborations across CMOs, universities, hospitals, and CROs, plus past partnerships with Michigan State University and Waterloo International, indicate readiness to engage in co-development and service-based models for faster go-to-market.

Expansion Potential Recent licensing interest and partnerships in regulated cannabinoid markets (Endopure Life Sciences) suggest opportunities to scale manufacturing, distribution, and regulatory-ready supply agreements in Latin America and other regulated regions.